[Biologicals and small molecules for systemic lupus erythematosus]

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Systemic lupus erythematosus (SLE) treatment is evolving with targeted therapies.
• Biologicals and small molecules represent a paradigm shift in managing SLE.
• Belimumab, a biologic for SLE, now has a subcutaneous formulation.

Purpose of the Study:

• To review the current landscape and future directions of targeted treatments for SLE.
• To highlight advancements in biologic and small molecule therapies for SLE.
• To discuss the potential of novel therapeutic targets in SLE management.

Main Methods:

• Review of clinical trial data for approved and investigational SLE therapies.
• Analysis of emerging therapeutic strategies including antibody-based treatments and small molecule inhibitors.
• Discussion of combination therapies and novel targets.

Main Results:

• Belimumab demonstrated efficacy in multiple trials, reducing organ damage.
• Anifrolumab targeting the type I interferon receptor was effective in Phase 3.
• Ustekinumab (anti-IL-12/23) is in Phase 3 trials; JAK inhibitors and BTK inhibitors show promise.

Conclusions:

• The treatment of SLE is becoming increasingly diverse with multiple targeted options.
• Combination therapies, such as belimumab with anti-CD20, are under consideration.
• Future SLE management will likely involve a personalized approach based on novel therapeutic targets.